4-Nitro-2-phenyl-pyrimidine | 127019-08-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Nitro-2-phenyl-pyrimidine
• 英文别名: Nitrophenylpyrimidine；4-nitro-2-phenylpyrimidine
• CAS: 127019-08-3
• 化学式: C₁₀H₇N₃O₂
• 分子量: 201.184
• InChiKey: GIDKRAVYSDBCAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-nitroso-2-phenylpyrimidine 在 臭氧 作用下， 以 氯仿 为溶剂， 以95%的产率得到4-Nitro-2-phenyl-pyrimidine
  参考文献：
  名称：

  Synthesis of 2- and 4-Nitropyrimidines and 2-Nitro-sym-triazines by ozonization of hydroxyamino and nitroso derivatives

  摘要：

  DOI：

  10.1007/bf00487433

文献信息

• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Xin Zhili

  公开号：US20050171132A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity and disorders associated with obesity such as non-insulin dependent diabetes mellitus.

  本发明涉及式（I）的化合物，或其治疗上适宜的盐或前药，以及该化合物的制备、含有该化合物的组合物以及在预防或治疗由胃饥饿素受体调节的疾病中使用该化合物，包括普拉德-威利综合症、进食障碍、体重增加、饮食和运动后体重减轻维持、肥胖症以及与肥胖症相关的疾病，如非胰岛素依赖性糖尿病。
• Heterocyclic sodium/proton exchange inhibitors and method
  申请人：Ahmad Saleem

  公开号：US20050137216A1

  公开（公告）日：2005-06-23

  Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R 5 wherein R 5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R 1 , R 2 , R 3 and R 4 are as defined herein, and where X is N, R 1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

  所提供的杂环化合物是钠/质子交换（NHE）抑制剂，其结构如下 其中 n 为 1 至 5；X 为 N 或 C-R 5 其中 R 5 是 H、卤素、烯基、炔基、烷氧基、烷基、芳基或杂芳基；Z 是杂芳基高尔基，R 1 , R 2 , R 3 和 R 4 如本文所定义，其中 X 为 N，R 1 最好是芳基或杂芳基，可用作抗心绞痛和心脏保护剂。此外，还提供了一种利用上述杂环衍生物预防或治疗心绞痛、心脏功能障碍、心肌坏死和心律失常的方法。
• Oxidation of hydroxyamino- and nitrosopyrimidines. Synthesis of 2- and 4-nitropyrimidines
  作者：G. G. Moskalenko、V. F. Sedova、V. P. Mamaev

  DOI：10.1007/bf00479613

  日期：1989.8